Standard Holdings, the aquaculture genes, health and advanced nutrition corporation, has this morning announced that they have sold its state of the art shot manufacturing facility at Braintree, Kent, to the Government backed Cellular and Gene Therapy Massively increase.
The purchase is part of BEIS’ £100m investment programme to boost the particular UK’s capacity to quickly scale-up manufacturing of a Covid-19 vaccine.
Along with Innovate UK and the Cellular and Gene Therapy Massively increase, the Government initiative will improve the existing manufacturing facility to create the particular fully licensed new center. Doing so will also increase the UK’s resilience and preparedness in order to emerging diseases like coronavirus, whilst creating new high-skilled jobs and helping to gas the UK’s economic recuperation.
The new center is vital to the government’s coronavirus programme to boost capacity to build up and mass produce vaccines. The facility will have the particular capabilities to rapidly scale-up manufacturing of a Covid-19 shot to millions of doses, plus gene therapies to treat and stop disease.
Business Secretary Alok Sharma said: “We are taking all necessary procedure for ensure we can vaccinate the general public as soon as a successful COVID-19 shot becomes available.
“This new Cellular and Gene Therapy Massively increase Manufacturing Innovation Centre, together with crucial investment in abilities, will support our attempts to rapidly produce an incredible number of doses of a coronavirus shot while ensuring the UK may respond quickly to possible future pandemics. ”
Philip George, Chairman of Standard Holdings, commented: “I am extremely delighted that Benchmark has been capable of being part of the UK solution pertaining to vaccine manufacturing. We were along the way of evaluating this field when Covid-19 broke, plus following communications with Friend Patrick Vallance, the Government Shot Taskforce, and with special due to hard work of Kate Bingham and her team, this is actually the outcome. I am delighted that we get a long-term solution for your workforce, which has always been the desired outcome. I would like in order to highlight the Government’ s i9000 foresight in identifying the options here and moving rapidly on this decision.
“I am proud to express that Benchmark is getting out of the Covid-19 lockdown time period in a stronger financial position compared to we entered, due to our own focus on completing our beautifully shaped restructuring programme. ”
BEIS purchases vaccine manufacturing facility included in £100m investment to produce millions of doses of covid-19 vaccine
SourceTagged with: BUSINESS NEWS • ECONOMIC NEWS • MAKE MONEY